CLOs on the Move

Sapient

www.sapient.bio

 
Sapient enables discovery of circulating biomarkers at unprecedented speed & scale, providing a deeper understanding of human biology to align patients & drug therapies.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.sapient.bio
  • 10421, Wateridge Circle
    San Diego, CA USA 92121
  • Phone: 858.290.7010

Executives

Name Title Contact Details
Vinay Bhupathy
General Counsel Profile

Similar Companies

Summit Therapeutics

We are a clinical-stage drug discovery and development company advancing innovative therapies to significantly advance the current standard of treatment for serious unmet medical needs.

CARIS MPI

CARIS MPI is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

BiOptix

BiOptix Diagnostics is a privately held firm based in Boulder, Colorado, with leading investments from Boulder Ventures, Remeditex and Rusnano.  BiOptix has developed a new class of analytical biosensor instrumentation utilizing a patented high-throughput label-free technology known as ESPR – Enhanced Surface Plasmon Resonance. BiOptix instrumentation allows researchers to study label-free protein-protein and protein-small molecule interaction—with high sensitivity and high throughput. Applications include: Protein-small molecule interactions, protein-protein kinetics, antibody affinities and epitope mapping, oligosaccharide characterization, nucleic acid (DNA-DNA or DNA-RNA) hybridization and biomolecule concentration measurements.

Theravance

Theravance, Inc. is focused on maximizing the potential value of the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R), with the intention of providing capital returns to stockholders. Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement with GSK, Theravance is eligible to receive the associated royalty revenues from RELVAR(R)/BREO(R) ELLIPTA(R) (fluticasone furoate/vilanterol, "FF/VI"), ANORO(R) ELLIPTA(R) (umeclidinium bromide/vilanterol, "UMEC/VI") and if approved and commercialized, VI monotherapy. Theravance is also entitled to a 15% economic interest in any future payments made by GSK under agreements entered into prior to the spin-off of Theravance Biopharma, and since assigned to Theravance Respiratory Company, LLC, relating to the combination of UMEC/VI/FF and the Bifunctional Muscarinic Antagonist-Beta2 Agonist (MABA) program, as monotherapy and in combination with other therapeutically active components, such as an inhaled corticosteroid, and any other product or combination of products that may be discovered and developed in the future under these agreements with GSK (other than RELVAR(R)/BREO(R) ELLIPTA(R), ANORO(R) ELLIPTA(R) and VI monotherapy).

CG Therapeutics Inc

CG Therapeutics Inc is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.